Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4465-4474

  Souliotis, Vassilis L ^a   Dimopoulos, Meletios A ^b   Sfikakis, Petros P ^b  

^a INSTITUTE OF BIOLOGY   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; CHLORMETHINE DERIVATIVE; CYCLOPHOSPHAMIDE; MELPHALAN; ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA ADDUCT; DNA CROSS LINKING; DNA EXTRACTION; DNA REPAIR; DNA STRAND; DOSE RESPONSE; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; HUMAN; IN VITRO STUDY; LEUKOCYTE; MALE; MULTIPLE MYELOMA; ONCOGENE; ONCOGENE N RAS; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CROSS-LINKING REAGENTS; CYCLOPHOSPHAMIDE; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; FEMALE; GENES, P53; GENES, RAS; HUMANS; LYMPHOCYTES; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA;

EID: 0141995075     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Osborne, M. R., Wilman, D. E. V., and Lawley, P. D. Alkylation of DNA by the nitrogen mustard bis(2-chloroethyl)methylamine. Chem. Res. Toxicol., 2: 316-320, 1995.
2. Colvin M. The alkylating agents. In: M. Chabner (ed.), Pharmacological Principles of Cancer Treatment, pp. 276-308. Philadelphia: W. B. Saunders Co., 1982.
3. Kohn K. W. Molecular mechanisms of crosslinking by alkylating agents and platinum complexes. In: A. C. Sartorelli, J. S. Lazlo, and J. R. Bertino (eds.), Molecular Actions and Targets for Cancer Chemotherapy Agents, pp. 3-16. New York: Academic Press, Inc., 1981.
4. Grant, D. F., Bessho, T., and Reardon, J. T. Nucleotide excision repair of melphalan monoadducts. Cancer Res., 22: 5196-5200, 1998.
5. Chaney, S. G., and Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J. Natl. Cancer Inst., 19: 1346-1360, 1996.
6. Dronkert M. L., and Kanaar R. Repair of DNA interstrand cross-links. Mutat. Re., 486: 217-247, 2001.
7. Friedman O. M., Myles A., and Colvin M. Cyclophosphamide and related phosphoramide mustards: current status and future perspectives. In: A. Rosowsky (ed.), Advances in Cancer Chemotherapy, pp. 143-204. New York: Marcel Dekker, Inc., 1979.
8. De Vita, S., Neri, R., and Bombardieri, S. Cyclophosphamide pulses in the treatment of rheumatic diseases: an update. Clin. Exp. Rheumatol., 9: 179-193, 1991.
9. Gibbons, R. B., and Westerman, E. Acute nonlymphocytic leukemia following short-term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis. Arthritis Rheum., 31: 1552-1554, 1988.
10. Ortiz, A., Gonzalez-Parra, E., Aloarez-Costa, G., and Egido, J. Bladder cancer after cyclophosphamide therapy for lupus nephritis. Nephron. 60: 378-379, 1992.
11. Montgomery, J. A., and Struck, R. F. The relationship of the metabolism of anticancer agents to their activity. Prog. Drug Res., 17: 320-409, 1973.
12. Maccubbin, A. E., Caballes, L., Riordan, J. M., Huang, D. H., and Gurtoo, H. L. A cyclophosphamide/DNA phosphoester adduct formed in vitro and in vivo. Cancer Res., 51: 886-892, 1991.
13. Osborne, M. R., and Lawley, P. D. Alkylation of DNA by melphalan and special reference to adenine derivatives and adenine-guanine cross-linking. Chem.-Biol. Interact., 89: 49-60, 1993.
14. IARC. Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man, Vol. 9, pp. 167-180. Lyon, France: International Agency for Research on Cancer, 1975.
15. Alexanian, R., and Dimopoulos, M. A. The treatment of multiple myeloma. N. Engl. J. Med., 330: 484-489, 1994.
16. Hanawalt, P. C. Heterogeneity of DNA repair at the gene level. Mutat. Res., 247: 203-211, 1991.
17. Mullenders, L. H., Vrieling, H., Venema, J., and van Zeeland, A. A. Hierarchies of DNA repair in mammalian cells: biological consequences. Mutat. Res., 250: 223-228, 1991.
18. Wassermann, K., Kohn, K. W., and Bohr, V. A. Heterogeneity of nitrogen mustard-induced DNA damage and repair at the level of the gene in Chinese hamster ovary cells. J. Biol. Chem., 265: 13906-13913, 1990.
19. + lymphocytes reflects transcription and proliferation. Mutat. Res., 363: 191-199, 1996.
20. + lymphocytes towards cisplatin. Neoplasma, 46: 342-348, 1999.
21. Sfikakis, P. P., Souliotis, V. L., Akbar, A. N., Katsilambros, N., Hoffbrand, V. A., and Panayiotidis, P. Regulation of bcl-2 and fas expression in primary activation of human peripheral lymphocytes is not sensitive to dexamethasone or cyclosporin-A. Hum. Immunol., 50: 121-126, 1996.
22. Sunters, A., Grimaldi, K. A., Souhami, R. L., and Hartley, J. A. Gene and human tumour cell line specific differences in nitrogen mustard induced DNA alkylation and interstrand crosslinking frequencies. Nucleic Acids Res., 26: 5617-5623, 1998.
23. Southern, E. M. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol., 98: 503-517, 1975.
24. Fenaux, P., Preudhomme, C., Quiquandon, I., Jonveaux, P., Lai, J. L., Vanrumbeke, M., Loucheux-Lefebre, M. H., Bauters, F., Berger, R., and Kerckaert, J. P. Mutations of the p53 gene in acute myeloid leukaemia. Br. J. Haematol., 80: 178-183, 1992.
25. Bashey, A., Gill, R., Levi, S., Farr, C. J., Clutterbuck, R., Millar, J. L., Pragnell, I. B., and Marshall, C. J. Mutational activation of the N-ras oncogene assessed in primary clonogenic culture of acute myeloid leukemia (AML): Implications for the role of N-ras mutation in AML pathogenesis. Blood, 79: 981-989, 1992.
26. Tilby, M. J., Mewell, D. R., Viner, C., Selby, P. J., and Deau C. J. Application of a sensitive immunoassay to the study of DNA adducts formed in peripheral blood mononuclear cells of patients undergoing high-dose melphalan therapy. Eur. J. Cancer, 29A: 681-686, 1993.
27. Reid, B. D., and Walker, I. G. The response of mammalian cells to alkylating agents. II. On the mechanism of the removal of sulfur-mustard-induced cross-links. Biochim. Biophys. Acta, 179: 179-188, 1968.
28. Hansson, J., Lewensohn, R., Ringborg, U., and Nilsson, B. Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res., 47: 2631-2637, 1987.
29. Ross, W. E., Ewig, R. A., and Kohn, K. W. Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links. Cancer Res., 38: 1502-1506, 1978.
30. Panasci, L., Henderson, D., Torres-Garcia, S. J., Skalski, V., Caplan, S., and Hutchins, M. Transport, metabolism, and DNA interaction of melphalan in lymphocytes from patients with chronic lymphocytic leukemia. Cancer Res., 48: 1972-1976, 1988.
31. Torres-Garcia, S. J., Cousineau, L., Caplan, S., and Panasci, L. Correlation of resistance to nitrogen mustards in chronic lymphocytic leukemia with enhanced removal of melphalan-induced DNA cross-links. Biochem. Pharmacol., 38: 3122-3123, 1989.
32. Hengstler, J. G., Fuchs, J., and Oesch F. DNA strand breaks and DNA cross-links in peripheral mononuclear blood cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin. Cancer Res., 52: 5622-5626, 1992.
33. DeNeve, W., Valeriote, F., Edelstein, M., Everett, C., and Bischoff, M. In vivo DNA cross-linking by cyclophosphamide: comparison of human chronic lymphatic leukemia cells with mouse L1210 leukemia and normal bone marrow cells. Cancer Res., 49: 3452-3456, 1989.
34. Kaldor, J. M., Day, N. E., Clarke, E. A., van Leeuwen, F. E., Henry-Amar, M., Fiorentino, M. V., Bell, J., Pedersen, D., Band, P., and Assouline, D. Leukemia following Hodgkin's disease. N. Engl. J. Med., 322: 7-13, 1990.
35. Henne T., and Schmahl D. Occurrence of second primary malignancies in man: a second outlook. Cancer Treat. Rev., 12: 77-94
36. Bashey, A., Gill, R., Levi, S., Farr, C. J., Clutterbuck, R., Millar, J. L., Pragnell, I. B., and Marshall, C. J. Mutational activation of the N-ras oncogene assessed in primary clonogenic culture of acute myeloid leukemia (AML): implications for the role of N-ras mutation in AML pathogenesis. Blood, 79: 981-989, 1992.
37. Osborne, M. R., Lawley, P. D., Crofton-Sleigh, C., and Warren, W. Products from alkylation of DNA in cells by melphalan: human soft tissue sarcoma cell line RD and Escherichia coli WP2. Chem.-Biol. Interact., 97: 287-296, 1995.
38. Fernberg, J. O., Lewensohn, R., and Skog, S. Cell cycle arrest and DNA damage after melphalan treatment of the human myeloma cell line RPMI 8226. Eur. J. Haematol., 47: 161-167, 1991.
39. Lawley, P. D., and Phillips, D. H. DNA adducts from chemotherapeutic agents. Mutat. Res., 355: 13-40, 1996.
40. Ringborg, U., Hansson, J., Jungnelius, U., Lewensohn, R., and Skog, S. Melphalan-induced DNA cross-linking and inhibition of DNA and RNA synthesis in human melanoma and lymphoblast cells. Anticancer Res., 10: 297-301, 1990.
41. Mu, D., Bessho, T., Nechev, L. V., Chen, D. J., Harris, T. M., Hearst, J. E., and Sancar A. DNA interstrand cross-links induce futile repair synthesis in mammalian cell extracts. Mol. Cell. Biol., 20: 2446-2454, 2000.
42. Ozols, R. F., Hogan, W. M., and Young, R. C. Direct cloning of human ovarian cancer in soft agar: clinical limitations and pharmacologic applications. Recent Results Cancer Res., 94: 41-50, 1984.
43. Kaufmann, M. Biochemical short-term predictive assay: results of correlative trials in comparison to other assays. Recent Results Cancer Res., 94: 151-160, 1984.
44. 6-methylguanine in humans and rodents treated with procarbazine. Carcinogenesis (Lond.), 15: 1675-1680, 1994.
45. 6-methylguanine in human leukocyte DNA after intravenous exposure to dacarbazine. Carcinogenesis (Lond.), 12: 285-288, 1991.
46. Fichtinger-Schepman, A. M., van der Velde-Visser, S. D., van Dijk-Knijnenburg, H. C., van Oosterom, A. T., Baan, R. A., and Berends, F. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res., 50: 7887-7894, 1990.
47. Parker, R. J., Gill, I., Tarone, R., Vionnet, J. A., Grunberg, S., Muggia, F. M., and Reed, E. Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis (Lond.), 12: 1253-1258, 1991.
48. Spanswick, V. J., Craddock, C., Sekhar, M., Mahendra, P., Shankaranarayana, P., Hughes, R. G., Hochhauser, D., and Hartley, J. A. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood, 100: 224-229, 2002.